789 related articles for article (PubMed ID: 20154508)
1. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
[TBL] [Abstract][Full Text] [Related]
2. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid.
Frisardi V; Solfrizzi V; Imbimbo PB; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Seripa D; Pilotto A; Capurso A; Panza F
Curr Alzheimer Res; 2010 Feb; 7(1):40-55. PubMed ID: 19939231
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.
Panza F; Solfrizzi V; Frisardi V; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Capurso A; Imbimbo BP
Drugs Aging; 2009; 26(7):537-55. PubMed ID: 19655822
[TBL] [Abstract][Full Text] [Related]
4. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
5. [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].
Schneider A; Falkai P; Papassotiropoulos A
Nervenarzt; 2010 Nov; 81(11):1289-90, 1292, 1294, passim. PubMed ID: 20842339
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
9. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.
Phiel CJ; Wilson CA; Lee VM; Klein PS
Nature; 2003 May; 423(6938):435-9. PubMed ID: 12761548
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
Pinheiro L; Faustino C
Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
[TBL] [Abstract][Full Text] [Related]
11. REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.
Panza F; Frisardi V; Imbimbo BP; Capurso C; Logroscino G; Sancarlo D; Seripa D; Vendemiale G; Pilotto A; Solfrizzi V
CNS Neurosci Ther; 2010 Oct; 16(5):272-84. PubMed ID: 20560993
[TBL] [Abstract][Full Text] [Related]
12. Status and future directions of clinical trials in Alzheimer's disease.
Plascencia-Villa G; Perry G
Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
[TBL] [Abstract][Full Text] [Related]
13. Roles of glycogen synthase kinase 3 in Alzheimer's disease.
Cai Z; Zhao Y; Zhao B
Curr Alzheimer Res; 2012 Sep; 9(7):864-79. PubMed ID: 22272620
[TBL] [Abstract][Full Text] [Related]
14. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
[TBL] [Abstract][Full Text] [Related]
15. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
16. The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.
Lanzillotta A; Sarnico I; Benarese M; Branca C; Baiguera C; Hutter-Paier B; Windisch M; Spano P; Imbimbo BP; Pizzi M
J Mol Neurosci; 2011 Sep; 45(1):22-31. PubMed ID: 21181298
[TBL] [Abstract][Full Text] [Related]
17. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
Suzuki K; Iwata A; Iwatsubo T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies for Alzheimer's disease.
Barten DM; Albright CF
Mol Neurobiol; 2008; 37(2-3):171-86. PubMed ID: 18581273
[TBL] [Abstract][Full Text] [Related]
19. Disease-modifying therapies in Alzheimer's disease: how far have we come?
Hüll M; Berger M; Heneka M
Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
[TBL] [Abstract][Full Text] [Related]
20. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
Ling S; Zhou J; Rudd JA; Hu Z; Fang M
Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]